UroGen Pharma Book Value Per Share Growth & History (URGN)
UroGen Pharma's book value per share was -$2.18 for fiscal 2025.
View full UroGen Pharma company overviewUroGen Pharma annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | -$2.18 | -$1.97 | — |
| 2024 | 2024-12-31 | -$0.21 | $1.80 | — |
| 2023 | 2023-12-31 | -$2.01 | $1.86 | — |
| 2022 | 2022-12-31 | -$3.86 | -$4.24 | — |
| 2021 | 2021-12-31 | $0.37 | -$3.97 | −91.38% |
| 2020 | 2020-12-31 | $4.35 | -$4.23 | −49.31% |
| 2019 | 2019-12-31 | $8.58 | $3.02 | +54.33% |
| 2018 | 2018-12-31 | $5.56 | $0.57 | +11.52% |
| 2017 | 2017-12-31 | $4.98 | -$2.09 | −29.55% |
| 2016 | 2016-12-31 | $7.07 | -$0.00 | −0.05% |
| 2015 | 2015-12-31 | $7.08 | — | — |
UroGen Pharma quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | -$2.71 | -$0.69 | — |
| Q1 2026 | 2026-03-31 | -$2.55 | -$1.54 | — |
| Q4 2025 | 2025-12-31 | -$2.18 | -$1.97 | — |
| Q3 2025 | 2025-09-30 | -$2.47 | -$3.07 | — |
| Q2 2025 | 2025-06-30 | -$2.02 | -$2.76 | — |
| Q1 2025 | 2025-03-31 | -$1.01 | $0.10 | — |
| Q4 2024 | 2024-12-31 | -$0.21 | $1.80 | — |
| Q3 2024 | 2024-09-30 | $0.60 | $1.60 | — |
| Q2 2024 | 2024-06-30 | $0.74 | $6.63 | — |
| Q1 2024 | 2024-03-31 | -$1.11 | $3.86 | — |
| Q4 2023 | 2023-12-31 | -$2.01 | $1.86 | — |
| Q3 2023 | 2023-09-30 | -$1.00 | $1.76 | — |
| Q2 2023 | 2023-06-30 | -$5.89 | -$4.09 | — |
| Q1 2023 | 2023-03-31 | -$4.97 | -$4.22 | — |
| Q4 2022 | 2022-12-31 | -$3.86 | -$4.24 | — |
| Q3 2022 | 2022-09-30 | -$2.75 | -$4.16 | — |
| Q2 2022 | 2022-06-30 | -$1.80 | -$4.32 | — |
| Q1 2022 | 2022-03-31 | -$0.75 | -$4.19 | — |
| Q4 2021 | 2021-12-31 | $0.37 | -$3.97 | −91.38% |
| Q3 2021 | 2021-09-30 | $1.41 | -$4.05 | −74.22% |
| Q2 2021 | 2021-06-30 | $2.52 | -$3.97 | −61.18% |
| Q1 2021 | 2021-03-31 | $3.43 | -$3.66 | −51.60% |
| Q4 2020 | 2020-12-31 | $4.35 | -$4.23 | −49.31% |
| Q3 2020 | 2020-09-30 | $5.46 | -$4.61 | −45.77% |
| Q2 2020 | 2020-06-30 | $6.48 | -$4.30 | −39.86% |
| Q1 2020 | 2020-03-31 | $7.09 | -$4.45 | −38.55% |
| Q4 2019 | 2019-12-31 | $8.58 | $3.02 | +54.33% |
| Q3 2019 | 2019-09-30 | $10.07 | $3.64 | +56.55% |
| Q2 2019 | 2019-06-30 | $10.78 | $3.62 | +50.52% |
| Q1 2019 | 2019-03-31 | $11.54 | $3.54 | +44.19% |
| Q4 2018 | 2018-12-31 | $5.56 | $0.57 | +11.52% |
| Q3 2018 | 2018-09-30 | $6.43 | — | — |
| Q2 2018 | 2018-06-30 | $7.16 | — | — |
| Q1 2018 | 2018-03-31 | $8.00 | — | — |
| Q4 2017 | 2017-12-31 | $4.98 | -$2.09 | −29.55% |
| Q4 2016 | 2016-12-31 | $7.07 | — | — |
UroGen Pharma book value per share trends
Over the last five fiscal years, UroGen Pharma's book value per share decreased from $4.35 to -$2.18, a change of -$6.53. The latest reported quarter, Q2 2026, shows -$2.71.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review UroGen Pharma source filings ↗